Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors.

Levstek, Tina; Karun, Tina; Rehberger Likozar, Andreja; Sebestjen, Miran; Trebusak Podkrajsek, Katarina

Levstek, Tina; Karun, Tina; Rehberger Likozar, Andreja; Sebestjen, Miran; Trebusak Podkrajsek, Katarina.

Afiliação

Levstek T; Laboratory for Translational Medical Biochemistry, Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia.
Karun T; Clinical Institute for Special Laboratory Diagnostics, University Children's Hospital, University Medical Centre Ljubljana, Vrazov trg 1, 1000 Ljubljana, Slovenia.
Rehberger Likozar A; Laboratory for Translational Medical Biochemistry, Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia.
Sebestjen M; Department of Vascular Diseases, University Medical Centre Ljubljana, Zaloska cesta 7, 1000 Ljubljana, Slovenia.
Trebusak Podkrajsek K; Department of Vascular Diseases, University Medical Centre Ljubljana, Zaloska cesta 7, 1000 Ljubljana, Slovenia.

Genes (Basel) ; 14(3)2023 03 03.

Article em En | MEDLINE | ID: mdl-36980904

Assuntos

Doença da Artéria Coronariana; MicroRNAs; Humanos; Pró-Proteína Convertase 9/genética; MicroRNAs/genética; Inibidores de PCSK9; Doença da Artéria Coronariana/tratamento farmacológico; Doença da Artéria Coronariana/genética; Lipoproteína(a)/genética; Lipoproteínas LDL; Subtilisinas

Palavras-chave

PCSK9; PCSK9 inhibitors; biomarker; cardiovascular disease; lipid parameters; lipoprotein(a); microRNA

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença da Artéria Coronariana / MicroRNAs Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google